Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Major Shareholder Growth N. V. Biotech Buys 150,000 Shares

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Rating) major shareholder Growth N. V. Biotech acquired 150,000 shares of the business’s stock in a transaction on Monday, April 18th. The shares were purchased at an average cost of $3.29 per share, for a total transaction of $493,500.00. Following the completion of the acquisition, the insider now […]

Related Keywords

Stifel Nicolaus ,Morgan Stanley ,Securities Exchange Commission ,Zacks Investment Research ,Norges Bank ,Renaissance Technologies ,Nasdaq ,Bioimpact Capital ,Capital Management ,Diamond Therapeutics Inc ,Black Diamond Therapeutics ,Get Rating ,Exchange Commission ,Diamond Therapeutics ,Impact Capital ,Investment Research ,Nasdaq Bdtx ,Bdtx ,Medical ,Insider Trading ,Nsider Trades ,Stocks ,